Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations.

Abstract excerpt

Human protein kinases have been established as promising druggable targets in cancer therapy. However, a large number of acquired drug-resistant kinase mutations are observed after first- and second-line kinase inhibitor treatments, largely limiting the application of small-molecule inhibitors in the targeted cancer therapy. Previously, the pan-kinase inhibitor staurosporine and its derivatives have been reported...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Dose-Response Relationship, Drug
• Share to Drug Resistance, Neoplasm
• Share to Drug Screening Assays, Antitumor